Novel Antimicrobial Agents and Strategies
Marktplatzangebote
Gebraucht bestellen
Ein Angebot für € 87,34 €
  • Gebundenes Buch

By integrating knowledge from pharmacology, microbiology, molecular medicine, and engineering, researchers from Europe, the U.S. and Asia cover a broad spectrum of current and potential antimicrobial medications and treatments. The result is a comprehensive survey ranging from small-molecule antibiotics to antimicrobial peptides and their engineered mimetics, from enzymes to nucleic acid therapeutics, from metallic nanoparticles to photo- and sonosensitizers and to phage therapy. In each case, the therapeutic approaches are compared in terms of their mechanisms, likelihood to induce…mehr

Produktbeschreibung
By integrating knowledge from pharmacology, microbiology, molecular medicine, and engineering, researchers from Europe, the U.S. and Asia cover a broad spectrum of current and potential antimicrobial medications and treatments.
The result is a comprehensive survey ranging from small-molecule antibiotics to antimicrobial peptides and their engineered mimetics, from enzymes to nucleic acid therapeutics, from metallic nanoparticles to photo- and sonosensitizers and to phage therapy. In each case, the therapeutic approaches are compared in terms of their mechanisms, likelihood to induce resistance, and their efficiency in a global healthcare context.
Unrivaled knowledge for professionals in fundamental research, pharmaceutical development and clinical practice.
Autorenporträt
Professor David Andrew Phoenix, OBE, DUniv, AcSS, DSc studied Biochemistry and was later awarded a Doctor of Science by Liverpool University for his impact on the field. He has over 200 publications and has held chairs in the UK, Canada, China and Russia. He is a Fellow of the Royal Society of Chemistry, the Society of Biology, the Institute of Mathematics and its Applications and the Royal Society of Medicine. He was elected to Fellowship of the Royal College of Physicians (Edinburgh) for his contribution to medical research and education, made an Officer of the Most Excellent Order of the British Empire for servcies to Science and Higher Education and recognized as an Academician by the Academy of Social Sciences. He is currently the Vice Chancellor of London South Bank University.

Dr. Frederick Harris PhD studied at UCLan, graduating with a Bachelor of Science in Biochemistry and Microbiology in 1993 before gaining his Doctorate for work on the penicillin-binding proteins of Escherichia coli in 1998. Subsequently, he has undertaken research at Utrecht University and the Leibniz-Centre for Medicine and Biosciences, Germany. In 2000, Frederick started as a Research Fellow at UCLan and now has more than 75 publications to his name, which primarily focus on antimicrobial and anticancer peptides.

Dr. Sarah Rachel Dennison PhD graduated from the University of Wales, Bangor with a Bachelor of Science in Environmental Biology in 1999. Subsequently, she undertook postgraduate research in Biochemistry / Biophysics, which led to a doctorate in 2004. Currently, Sarah is a Research Associate at UCLan where she is investigating the role of amphiphilicity in the function of antimicrobial peptides using a number of biophysical techniques such as Langmuir Blodgettry and antimicrobial assays. She has produced over 50 publications from her research and parallel collaborative work.